Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.82 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.82 |
| ▸ | SMC2 | O95347 | 1/20 | 0.82 |
| ▸ | EGFR | P00533 | 1/20 | 0.82 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.82 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.82 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.82 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.82 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | NQO2 | P16083 | 1/20 | 0.69 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4546010 | 0.92 | MAP2K1 (0.87) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL26937962 | 0.90 | MAP2K1 (0.85) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL1038067 | 0.90 | MAP2K1 (0.85) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL21501424 | 0.90 | MAP2K1 (0.87) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL29555068 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL155456 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL29353582 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL30733321 | 0.89 | MAP2K1 (0.82) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL26928339 | 0.89 | MAP2K1 (0.82) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL30487260 | 0.89 | MAP2K1 (0.88) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663210-B1 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-7842816-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842816-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842816-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MAP2K1 170/4885MAP2K2 159/4885SMC2 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.